Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The European varicose vein treatment device market will be characterized by shift toward and a changing reimbursement landscape for endovenous ablation technologies, namely ERFA and ELA, which will compete with surgical stripping procedures through 2027.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for varicose vein treatment devices in Europe across a 10-year period.
Endovenous ablation varicose vein treatment options are becoming increasingly accessible in Europe.
What is the current reimbursement situation for ELA and ERFA procedures?
How will the recently approved MOCA and cyanoacrylate adhesive devices drive adoption?
Sclerotherapy use will expand through 2027.
What are some of the approved sclerosing agents on the market?
How will the introduction of polidocanol microfoam affect the market?
Surgical stripping remains the common procedure utilized in the treatment of varicose veins in some countries.
Why do these invasive procedures continue to be popular in some countries?
How will the increasing availability of minimally invasive treatment options impact surgical vein stripping procedure volumes?
Already a Client? Log in to access this report.
Shruthi Narendranath is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in heart valve and periphral vascular device markets. Shruthi holds a Master's degree in Bioinformatics from Cardiff University.